Somapacitan is a human growth hormone analog subcutaneous injection indicated for adults with growth hormone deficiency. This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
- Mechanism
- Curator reviewed · 4 references
Somapacitan binds to the growth hormone receptor and induces intracellular signalling to up-regulate insulin-like growth factor I (IGF-1). IGF-1 causes growth in bones and muscle tissue. Growth hormones more directly cause the fusion of myoblasts and myotubes to cause muscle fibre growth, activate neural stem cells, and induce chondrocyte proliferation.
- Primary indication
- Somapacitan is indicated for the treatment of pediatric patients aged 2.5 years and older with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature born small for gestational age (SGA) and...Curator reviewed · 5 structured indications
- Formula / weight
- C1038H1609N273O319S9
- First approval
- Canada, 2023 · United States, 2023 · European Union, 2021
- Also known as
- Sogroya · Somapacitan (genetical recombination) · somapacitan-beco
- Code names
- NN-8640 · NNC-0195-0092
- Brand names
Resolves to
What you can answer from here — as of September 05, 2026
Which drugs share a target with Somapacitan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account